Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy ... Other companies working in this area include Canadian group Sernova, which has a phase 1/2 trial on the ...

We tried Shark's vast vacuum lineup and explored the effectiveness of features like lift-away pods, dirt detection, and ...

"My prediction on the buzzwords of the year are really open-source models and agentic AI," said Don Woodlock, head of global healthcare ... the highest ROI area to apply AI solutions, she noted.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Subdural hematoma is an emergency in which bleeding occurs between the brain and skull. Learn how it’s treated and what the ...

New Zealand is now out of recession and Napier Health's in-person overnight care will continue following backlash over proposed cuts. Video / NZ Herald, Getty A man who died in hospital after he ...